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The breast cancer-associated T2A10 clone was originally isolated from a cDNA library enriched for tumour messenger ribonucleic
acids. Our survey of 125 microarrayed primary tumour tissues using affinity purified polyclonal antibodies has revealed that
corresponding protein is overexpressed in invasive breast cancer and is weakly expressed in kidney and prostate tumours. Now
known as RNF11, the gene encodes a RING-H2 domain and a PY motif, both of which mediate protein–protein interactions. In
particular, the PPPPY sequence of RNF11 PY motif is identical to that of Smad7, which has been shown to bind to WW domains of
Smurf2, an E3 ubiquitin ligase that mediates the ubiquitination and degradation of the TGFb receptor complex. Using various mutants
of RNF11 in GST pulldown and immunoprecipitation assays, we found that RNF11 interacts with Smurf2 through the PY motif,
leading to ubiquitination of both proteins. Smurf2 plays an active role in the repression of TGFb signalling, and our data indicate that
overexpression of RNF11, through its interaction with Smurf2, can restore TGFb responsiveness in transfected cells.
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Breast malignancy at the molecular level is partly due to genetic
mutations and deletions that result in the alteration of expression
and function of various cellular genes. Although progress has been
made in characterising some of these genes, the specific molecular
mechanisms underlying many of the cellular pathways remain to
be elucidated. Once identified, such differentially expressed genes
will be useful in monitoring disease progression and under-
standing the molecular mechanisms of tumour development. In
addition, the molecular definition of new genes involved in breast
tumours will yield novel targets for new therapeutic strategies.
The T2A10 gene was originally cloned as a partial cDNA from
a library enriched for breast tumour messenger ribonucleic acids
(mRNAs) (Burger et al, 1998). Subsequently, we extended
this cDNA sequence ‘in silico’ using overlapping expressed
sequence tags (ESTs) and cloned a full-length copy DNA (cDNA)
corresponding to a 2.4 kilobase (kb) mRNA (Kitching et al, 2003).
We found its open reading frame (ORF) to be identical to the
human ring-finger 11 (RNF11) protein (Seki et al, 1999).
The predicted amino-acid sequence for the longest RNF11 ORF
encodes a RING-H2 domain and a PY motif, both of which mediate
protein–protein interactions for proteins involved in signal
transduction pathways and ubiquitin (Ub)-mediated proteolysis.
PY motif sequences are found in a variety of regulatory proteins
including the AP-2 transcription factor, p53BP-2, RasGAP,
and Smads 2, 3 and 7 (Yagi et al, 1999). Each of these proteins
binds to specific WW domain containing proteins, such as YAP,
WWOX, Smurf1, Smurf2 and NEDD4 (Yagi et al, 1999;
Kavsak et al, 2000; Winberg et al, 2000; Conaway et al, 2002;
Suzuki et al, 2002; Yendamuri et al, 2003). Ubiquitination- and
proteasome-mediated degradation of proteins is an important
step in cellular signalling, and disruption of this process has
been implicated in many human diseases including cancer
(Hershko and Ciechanover, 1998). Similar to RNF11, Smad
proteins (Smads 2, 3 and 7) contain PY motifs that act as
substrates and adaptors for the Smurf2 E3 Ub ligase in the
transforming growth factor b (TGFb) signalling pathway (Mehra
and Wrana, 2002). TGFb is a multifunctional peptide that controls
proliferation, differentiation and other functions in normal and
transformed cells. TGFb signalling molecules have been shown to
have a crucial role in breast and other cancers (Attisano and
Wrana, 2002).
Here, we investigated RNF11 protein expression in an array of
125 human primary tumours, including mammary carcinomas,
and studied potential protein binding partners. The PY motif of
RNF11 suggests a link to TGFb signalling through interactions
with the WW-binding domains of Smurf2. The functionality of this
motif was tested by in vivo binding and ubiquitination assays with
Smurf2. Finally, we demonstrate that RNF11 overexpression can
preserve TGFb receptor responsiveness in mammalian cells.
METHODS
Antibodies
C14N polyclonal antibody was raised in rabbits against a synthetic
hexadecapeptide sequence derived from the RNF11 C-terminal
region conjugated to keyhole limpet haemocyanin (KLH). Rabbit Received 29 May 2003; revised 31 July 2003; accepted 5 August 2003
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column. FLAG (M2), b-actin and glutathione-S-transferase (GST)
antibodies were purchased from Sigma. Haemagglutinin (HA)
antibody (12CA5), which recognises a nonapeptide sequence
(YPYDVPDYA), derived from the influenza haemagglutinin
protein, was from Roche. Anti-polyhistidine (HIS-tag) antibody
was from R&D systems. Protein A-sepharose beads were from
Sigma and gluthathione sepharose beads were from Amersham
Pharmacia.
Tumour tissue microarray (TMA) and
immunohistochemistry (IHC)
Tumour cases were selected from the archives of the Department
of Anatomic Pathology, Sunnybrook and Women’s College Health
Sciences Centre. Following selection of tumour blocks and
verification of the diagnosis, tissue was anonymised by stripping
all identifiers from each case. Areas of cancer and normal tissue
elements were marked on haematoxylin and eosin (H&E) sections
by a pathologist (JZ). A multi TMA was assembled consisting of 20
breast, 15 prostate, 17 bladder, 16 colon, 11 head and neck, seven
lung, 17 renal and 22 pancreas carcinomas by punching 0.6mm
tissue cores from the donor block and transferring them to a
recipient block. A total of 125 cases were arrayed in duplicates
using two blocks for each case. The array was essentially
constructed and transferred onto slides following the TMA
methodology as described (Kononen et al, 1998).
Tumour-specific RNF11 expression was monitored by IHC using
the Histostain SP rabbit kit with DAB substrate from Zymed (San
Francisco, CA, USA). The primary RNF11 antibody (0.4mgml
 1,
1:125 dilution) was used to probe TMA sections processed and
evaluated as reported previously (Landberg et al, 2001). For
negative controls, RNF11 antibody was preincubated with the
RNF11 peptide (10:1 ratio with antibody) used for immunisation
1h prior to the reaction with the TMA. Results are representative
of three independent experiments.
Vectors
Human Flag-Smurf2 and HA-tagged deletion mutants of Smurf2,
HA-tagged Smad7, p3TP-Lux, polyhistidine (HIS) tagged Ubc3,
UbcH5a, UbcH5b, UbcH5c, and HA-tagged Ub are as described by
Kavsak et al (2000) and Bonni et al (2001). RNF11 and the
engineered mutants of RNF11 were derived from the RT–PCR
cloned ORF of RNF11 in vector plasmid pCMV-T2C using the
Quikchange Site Directed Mutagenesis Kit (Stratagene). For the
RNF11-mtPY construct, the tyrosine at position 40 was substituted
to alanine, and in the RNF11-mtRING construct the cysteines at
positions 89 and 93 were mutated to serine 89 and serine 93. The
RNF11-mtDouble mutant has both the PY and the Ring mutation.
Cell lines and transfection assays
HEK293T is a simian virus 40 (SV40) large T-antigen transformed
human embryonal kidney cell line that can be transiently
transfected, and is therefore commonly used to study protein–
protein interactions by immunoprecipitation (Di Guglielmo et al,
2003). The HEK293T cell line was maintained in high glucose DME
medium (Gibco) containing 10% FBS without antibiotics in 5%
CO2 atmosphere. HepG2 cells were maintained in minimal
essential medium (MEM) (Gibco) containing Earle’s salts, L-
glutamine, 1mM sodium pyruvate, 0.1mM nonessential amino
acids and 10% FBS in 5% CO2 atmosphere. For transfections,
1 10
6 cells were plated in triplicate in 100-mm dishes and grown
overnight, medium was changed 2h prior to transfection. Each
plasmid DNA (2–5mg) was mixed with 250mM CaCl2 and 2  HBS
(280mM NaCl, 50mM HEPES, 1.5mM sodium phosphate (pH 7.05))
and incubated at room temperature for 15min. The precipitate was
then added to exponentially growing cells (Hoodless et al, 1996).
One of at least three similar experiments is shown.
Immunoprecipitation and Western blots
Cell lysates were immunoprecipitated (IP) with mouse anti-FLAG,
anti-GST or anti-HA antibody, and Western blots were performed
as described (Winberg et al, 2000). Briefly, 42–48h post-
transfection, cells were lysed in 900ml of lysis buffer (50mM Tris
pH 7.6, 150mM NaCl, 0.1% NP-40) containing protease inhibitors.
Cell lysates were incubated with antibodies for 1h at 41C. Protein
A-sepharose beads were added to the lysates, which were then
incubated for 30min at 41C, and the resulting immunoprecipitates
were washed with lysis buffer three times. Immunoprecipitates and
aliquots of total cell lysates were separated by sodium dodecylsul-
phate–polyacrylamide gel electrophoresis (SDS–PAGE) and
transferred to a Hybond-P membrane (Amersham). Antibody
reactive proteins were detected using horse radish peroxidase
(HRP)-conjugated secondary antibodies and visualised by chemi-
luminesence (Amersham). Representative Western blots from one
of at least three similar experiments are shown. C14N antibody
competition with the immunising peptide was carried out on
duplicate Western blots using a 10:1 ratio of peptide to antibody.
Transcriptional response assay
HepG2 is one of the tumour lines that retain TGFb responsiveness
in culture and is therefore used here (Di Guglielmo et al, 2003). For
TGFb inducible luciferase reporter assays, HepG2 cells were
transiently transfected with the reporter plasmid (3TP-Lux),
pCMV-b-gal and the indicated constructs or with the empty
vector alone. To induce the luciferase reporter, cells were treated
overnight with 100pM of TGFb as described (Hayashi et al, 1997).
Luciferase activity in cell lysates was measured using the luciferase
assay system in a Berthold Lumat LB 9501 luminometer
(Promega).
RESULTS
RNF11 protein is overexpressed in breast tumours
RNF11 protein expression in primary tumours was monitored by
IHC using affinity purified anti-human RNF11 polyclonal antibody
on a TMA composed of duplicate punches from 125 primary
tumours representing eight different histologies. IHC results for
the TMA are summarised in Table 1, and indicate that RNF11 is
predominantly expressed in the cytoplasm of cancer cells (Figure
1A, B, Table 1). Staining of primary breast tissues with anti-RNF11
antibody showed that the corresponding protein is high in cancer
cells, but low in normal ductal structures and absent in
surrounding stroma (Figure 1B). Strong cytoplasmic RNF11
staining was found in 490% of the invasive breast cancer cases,
in adenocarcinomas of the pancreas (78%), colon cancer (47%)
and in bladder tumours (31%) (Table 1, Figure 1). Table 2
summarises the RNF11 staining with clinicopathologic features
such as oestrogen and progesterone receptor status (ER and PR),
Bloom–Richardson grading (BR grade), lymph node (LN) status
and histology.
Modest RNF11 expression was seen in 63% of the head and neck
tumours, and 57% of the lung tumours, whereas renal and prostate
carcinomas stained only weakly positive for RNF11 protein
(B10%) (Figure 1B, Table 1). The specificity of RNF11 staining
in the arrayed tumour tissues was confirmed by probing control
sections with RNF11 antibody that had been preincubated with the
hexa-decapeptide used for immunisation (Figure 1A). Although
RNF11 protein expression was predominantly located in the
cytoplasm in all eight tissue types on the TMA (Figure 1), some
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snuclear RNF11 accumulation was observed in lung, renal, and head
and neck cancers (Figure 1B).
RNF11 interacts with Smurf2 through the PY motif
In order to test RNF11 interaction with Smurf2, we transiently
transfected the HEK293T cell-line with GST-tagged RNF11 and
three mutant RNF11 constructs together with a FLAG-tagged
Smurf2 expression vector (Figure 2). The GST-tagged RNF11
mutants included RNF11-mtPY in which the tyrosine of the PY
motif was mutated to alanine, RNF11-mtRing, where the first two
cysteines in the RING-finger domain were replaced by two serines
and the RNF11-mtDouble having both mutations. GST pulldown of
lysates from cultures cotransfected with Flag-Smurf2 and wild-type
GST-RNF11 isolated a protein corresponding to Flag-tagged
Smurf2 (as shown by anti-Flag Western blot), but not from lysates
of cells cotransfected with Flag-Smurf2 and the GST-vector alone
(Figure 2A). This result was confirmed by anti-Flag immunopre-
cipitation and GST immunoblot of lysates from HEK293T cells
Breast Pancreas
RNF11
RNF11
+
Peptide
Lung
Breast Breast Bladder
Colon Head and Neck Lung
Kidney Pancreas Prostate
A
B
Figure 1 RNF11 protein expression in tumour tissues. (A) TMA
sections stained with anti-RNF11 antibody and anti-RNF11 antibody
preincubated with synthetic peptide used for immunisation (magnification
 40). (B) Representative examples of RNF11-positive tumour tissues
from eight different histologies as indicated on top of the each picture.
Invasive breast carcinoma cells (red arrow) are strongly RNF11 positive as
compared to surrounding stroma (green arrow) and normal breast glands
(blue arrow) (magnification  200).
Table 1 Immunohistochemical staining with RNF11 antibody in 125
microarrayed tumour tissue sections; duplicate micropunches of each
tumour were remounted and sectioned to produce the microarray
Tumour type No. evaluated Positive (%) IHC staining intensity
Breast 20 90 +++
Bladder 17 31 ++
Colon 16 47 ++
Head and neck 11 63 +
Kidney 17 11 +
Lung 7 57 +
Pancreas 22 78 ++
Prostate 15 10 +
+¼weak; ++¼intermediate; +++¼strong to very strong immunoperoxidase/DAB
intensity (brown).
Table 2 RNF11 Expression in relation to clinicopathological parameters
in breast cancers
Histology # RNF11 BR grade ER PR LN
INV, ductal NOS 18 2.2670.35 II–III 14+/4  7+/11  7+/8 /3NK
INV, ductal papillary 2 2 271 II–III 1+/1  2  2 
INV¼invasive; #¼number of cases; BR grade¼Bloom–Richardson grading system;
ER¼oestrogen receptor status; PR¼progesterone receptor status; LN¼lymph
node status; NK¼not known; RNF11¼mean staining intensity7s.d. of IHC score.
kDa
66
Flag IP 
Flag blot
Flag IP 
GST blot
96
46
Flag-Smurf 2
GST-RNF11
IgG
+
+
+
+
GST-RNF11
−
−
−−
−
−
−
−
−
−
−
−
GST-RNF11mtPY
GST-RNF11mtDouble
GST-RNF11mtRING
F
L
A
G
-
S
m
u
r
f
2
 
(
W
h
o
l
e
-
c
e
l
l
 
l
y
s
a
t
e
)
F
L
A
G
-
S
m
u
r
f
2
 
+
 
G
S
T
-
R
N
F
1
1
G
S
T
 
v
e
c
t
o
r
 
+
 
F
L
A
G
-
S
m
u
r
f
2
96
66
GST pulldown
FLAG blot
kDa
46
30
GST pulldown
GST blot
Flag-Smurf 2
GST-RNF11
GST
GST pulldown A
B
Figure 2 RNF11 interacts with Smurf2 through the PY motif. (A) FLAG
and GST Western blots of whole-cell lysates and GST pulldowns or (B)
FLAG immunoprecipitates from HEK293T cells transiently transfected with
the Flag-Smurf2 expression vector and wild-type GST-RNF11 or its
mutants using the calcium phosphate precipitation method.
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stransfected with Flag-Smurf2 and each of the GST-RNF11
constructs, the wt RNF11, the PY mutant, the RING-H2 mutant
or the double mutant (Figure 2B). GST-RNF11 bands were
observed only with wild-type RNF11 and the Ring mutant but
not with the RNF11-mtPY or RNF11 double mutant, indicating
that RNF11 interacts with Smurf2 through its PY motif.
Smurf2 interaction with RNF11 requires WW domains 2
and 3
In order to identify which of three WW domains in Smurf2 could
mediate RNF11 binding, HEK293T cells were cotransfected with
expression vectors for GST-RNF11 and each of three HA-tagged
Smurf2 deletion mutants (Figure 3A). The HECT-Smurf2 mutant
contains no WW domains, and GST pulldown followed by anti-HA
Western blot did not resolve a band corresponding to HECT-
Smurf2, indicating that in the absence of WW domains, Smurf2
does not interact with RNF11 (Figure 3A, lane 6). No HA-tagged
Smurf2 band is seen in HA blots of GST pulldowns from cells
cotransfected with GST-RNF11 and WW1-Smurf2, indicating that
WW domain 1 is not sufficient for Smurf2–RNF11 interaction
(Figure 3A, lane 2). However, when Smurf2 deletion mutant
containing WW2 and WW3 domains was tested, a band
corresponding to WW2&3-Smurf2 protein can be seen on the
HA Western blot after GST pulldown using GST-RNF11 protein
(Figure 3A, lane 4). In all three cotransfections, the anti-HA
Western blot of whole-cell lysates shows that mutant HA-tagged
Smurf2 proteins were available for pulldown mediated by
interactions of GST-RNF11 and HA-Smurf2 proteins (Figure 3A,
lanes 1, 3 and 5).
Endogenous RNF11 interaction with Smurf2 WW domains was
examined by anti-RNF11 Western blot after HA pulldown of the
WW2&3-Smurf2 construct from transfected cells (Figure 3B). The
C14N anti-RNF11 antibody recognises an 18kDa band that is not
visible in the presence of the immunising peptide.
RNF11 interacts with UbcH5s but not with Ubc3
Most ubiquitination complexes require an E2 conjugating protein
to provide the Ub moiety for the E3 ligases or multisubunit E3
ligase complexes (Freemont, 2000; Joazeiro and AM Weissman,
2000; Thrower et al, 2000; Zheng et al, 2002). We found that
Smurf2 E3 ligase interacts with RNF11 through its WW domains
(Figures 2 and 3). RNF11 also contains a RING-H2 domain, some
examples of which are known to bind ubiquitin conjugating (Ubc)
proteins involved in ubiquitination (Freemont, 2000; Thrower et al,
2000; Zheng et al, 2002). This suggested to us that one or more Ubc
proteins might interact with RNF11, and this was tested by
cotransfection of HEK293T cells with epitope tagged expression
vectors for Ubc3 and UbcH5 a, b and c. GST pulldown was used to
extract and concentrate proteins associated with GST-RNF11, and
an anti-GST Western blot shows that this protein was present in all
the lysates. Ubc3 and three variants of UbcH5 were also found in
lysates transfected with His-tagged protein expression vectors for
each, as revealed by an anti-His tag Western blot of whole-cell
lysates (Figure 4). Interestingly, the His-tagged UbcH5 proteins,
but not the His-Ubc3 protein, are seen on the Western blot made
after GST pulldown of GST-RNF11. This indicates that RNF11
interacts with UbcH5s but not with Ubc3.
Ubiquitination of RNF11 by Smurf2 requires the PY motif
Smurf2 is a HECT-type E3 Ub ligase which suggests to us that
RNF11 may be one of its targets for ubiquitination. This was tested
α-HA blot
WW1-Smurf2 WW2&3-Smurf2 HECT-Smurf2
GST-PD WCL
2 1
GST-PD WCL
4 3
GST-PD WCL
6 5
Wild-type Smurf2 C2 WW3 HECT WW2 WW1
Smurf2 mutation C2 WW1 WW3 WW2 HECT
Construct
Lane
Sample
HA-WW2&3-Smurf2 +      − + −
-HA Pulldown
C14N Ab
+
C14N Peptide
C14N Ab
RNF11 19 kDa
A
B
Figure 3 GST–RNF11 interactions with Smurf2 mutants. WW1-Smurf-
is a mutant of Smurf2 lacking WW-binding domains 2 and 3. WW2&3 is a
deletion mutant of Smurf2 lacking the C2, WW1 and HECT domains.
HECT-Smurf2 is a deletion mutant of Smurf2 containing only the HECT
domain: (A) top panel: various domains in Smurf2; middle panel: HA
immunoblots of whole-cell lysates (WCL) of cells transfected with HA-
tagged Smurf2 mutants and GST-RNF11 and GST pulldown (GST-PD) of
the transfected cell lysates; bottom panel: schematics of the Smurf2
mutants. (B) Endogenous RNF11 interacts with WW domain of Smurf2.
Chemiluminescent detection of endogenous RNF11 with anti-RNF11
antibody in the presence (left panel) and absence (right panel) of the
immunizing peptide on Western blots containing proteins pulled down by
anti-HA agarose beads from cell extracts prepared from 293T cells
transfected by HA-Smrf2 WW2&3 construct.
-46
-14
-30
-21
-14
WCL
GST Pulldown
His-blot
GST pulldown
GST blot
UbcH5
Ubc3
−
−
−
His-UbcH5a
−
+
−
His-UbcH5b
+ −−− His-Ubc3
−
−
−
−
+
His-UbcH5c
+
+
+
GST-RNF11
+
+
GST-RNF11
UbcH5
-30
-21
Lane 12 3 4
Figure 4 RNF11 interacts with UbcH5s but not with Ubc3. GST and
His-Tag Western blots of whole-cell lysates and GST pulldowns from 293-
T cells cotransfected with GST-RNF11 and each of the His-tagged E2
protein expression vectors as indicated.
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tagged Ub and Ubc3 or UbcH5 constructs followed by immuno-
precipitation of ubiquitinated proteins with anti-HA or anti-Flag
antibody and anti-GST or anti-HA Western blotting (Figure 5).
Anti-HA immunoblotting showed ubiquitination of Smurf2 and
associated proteins immunoprecipitated by anti-Flag antibody
when RNF11 and UbcH5a were cotransfected with Smurf2
(Figure 5). Weak bands resulting from cotransfection with the
PY mutant of RNF11 suggest that this mutation severely reduces
ubiquitination of Smurf2 (Figure 5, lane 1). An anti-GST Western
blot of the same lysates also revealed bands corresponding to
ubiquitinated GST-RNF11 in lysates of cells cotransfected with
Flag-Smurf2 and UbcH5a (Figure 5, lane 5). In the absence of
Ubc5a, Flag-Smurf2 protein was not sufficient to allow immuno-
precipitation of either ubiquitinated RNF11 or ubiquitinated
Smurf2 (Figure 5, lane 3). Similarly, no ubiquitinated proteins
were seen on either blot in lysates transfected with Ubc3 (Figure 5,
lanes 2 and 3). As expected, anti-FLAG and anti-GST reactive
proteins were seen in whole-cell lysates transfected with constructs
for FLAG-Smurf2 and GST-RNF11.
RNF11 relieves Smurf2-mediated transcriptional inhibition
of a TGFb responsive promoter
Cooperative interaction between Smurf2 and Smad7 results in
inhibition of TGFb signalling by degradation of the TGFb receptor I
(Kavsak et al, 2000). The inhibitory activity of Smurf2 is dependent
on interaction of its WW domains with the PY motif of Smad7
(Kavsak et al, 2000). We have shown that the WW2 and WW3
domains of Smurf2 are necessary for interaction with RNF11
(Figure 3). RNF11 protein might therefore inhibit interactions
between Smad7 and Smurf2, thereby affecting TGFb signal
transduction. The effect of RNF11 on TGFb-dependent transcription
activation was investigated by transient cotransfection of RNF11
and 3TP Lux promoter–reporter plasmids (Figure 6). The 3TP Lux
reporter vector contains a TGFb responsive portion of the
plasminogen activator inhibitor (PAI) promoter linked to the
coding region of the firefly luciferase gene. The PAI promoter is
highly active in TGFb-treated cells and inactive in the absence of
TGFb (Figure 6). We found that its reporter gene activity is reduced
by more than seven-fold by cotransfection with the Smurf2
expression vector even in the presence of exogenous TGFb
(Figure 6). Interestingly, reporter gene activity is restored when
RNF11 is included in cotransfection with Smurf2. This relief of
inhibition depends upon the wild-type PY motif in RNF11, as the
RNF11 mtPY does not produce this effect when contransfected with
the Smurf2 vector in TGFb-treated HepG2 human hepatoma cells.
DISCUSSION
In this study, we chose the RNF11 gene for characterisation of its
protein expression and mechanisms of action in normal and
cancer cells because it was isolated from a tumour cell-enriched
cDNA library, is unique, and contains modular domains and
motifs known to interact with other proteins involved in
oncogenesis. TMA technology allowed for a rapid and simulta-
neous analysis of RNF11 protein expression in 125 primary
tumours microarrayed in duplicate by immunohistochemical
staining using anti-RNF11 antibody (Kononen et al, 1998; Land-
berg et al, 2001). Comparison of RNF11 expression between breast,
prostate, head and neck, kidney, colon and lung cancers revealed
that the majority of our tumour array specimens produced clear
immunostaining without any detectable background, and the
morphology of the tissues was well preserved (Figure 1). To
facilitate comparison of our results with published data, we
employed the commonly used semiquantitative evaluation of
protein expression based on distinct differences between strong,
moderate and lack of staining in tumour specimens developed with
immunoperoxidase methods (Kononen et al, 1998; Landberg et al,
2001). RNF11 was markedly overexpressed in breast and to a
somewhat lesser extent in pancreatic as well as colon cancer
samples, whereas it was only weakly expressed in prostate and
renal cell carcinomas (Table 1, Figure 1).
The RNF11 gene was originally cloned as T2A10, a cDNA
fragment from our library enriched for breast tumour-specific
mRNAs. We found it to be identical to the human RNF11 protein,
and it encodes modular domains and motifs known to interact
with other proteins involved in oncogenesis (Kitching et al, 2003).
Chief among these is the RING-H2-finger domain that could
facilitate protein–protein interaction(s) leading to the degradation
of specific substrate(s) involved in oncogenesis and the PY motif
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Figure 5 RNF11 is ubiquitinated in the presence of UbcH5a and Smurf2.
HA, GST and FLAG Western blots of anti-HA and Flag immunoprecipitates
or whole-cell lysates as indicated are shown. The cell lysates were prepared
from HEK293T cells cotransfected with HA-tagged ubiquitin and various
combinations of GST-RNF11 or its mutant GST-RNF11mtPY with Flag-
tagged Smurf2, and/or His-tagged E2 constructs as indicated.
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Figure 6 RNF11 affects TGFb responsive gene transcription. HepG2
cells were transiently transfected with 4mg of p3TP-Lux alone, RNF11 or
RNF11-mtPY mutant, and varying concentrations of Smurf2. Cells were
incubated overnight in the absence or presence of 100pM of TGFb and the
relative luciferase activity was measured in cell lysates. Luciferase activity
was normalised to b-galactosidase activity and is expressed as the
mean7s.d. of triplicates from a representative experiment.
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type E3 ligases such as NEDD4, AIP4 and Smurf2. The PPPPY
motif sequence of RNF11 is identical to that of Smads 2, 3 and 7,
which have been shown to bind WW domains of Smurf2 Ub ligase
and mediate the ubiquitination and degradation of various target
proteins (Coopman et al, 2000; Longnecker et al, 2000). Smurf2
plays a key role in the ubiquitination and proteasomal degradation
of receptor-activated Smad2 and Smad3, and corepressor SnoN
(Bonni et al, 2001; Mizuide et al, 2003). The Smurf2 and Smad7
complex ubiquitinates TbRI, a key event resulting in degradation
of the receptor and TGFb resistance in cancer cells (Kavsak et al,
2000).
Through site-directed mutagenesis, we showed that the tyrosine
residue of the RNF11 PY motif is essential for binding to Smurf2
(Figure 2). Indeed, mutation of the PY motif, but not the RING-H2,
eliminates the interaction with Smurf2 (Figure 2). We also
investigated which of the Smurf2 WW domains might be necessary
for interaction with the PY domain of RNF11 (Figure 3). Only wild-
type Smurf2 and the mutant that contains the WW2 and WW3
domains were able to interact with RNF11, indicating that
interaction of RNF11 with Smurf2 does not require the WW1
domain (Figure 3).
RNF11 binding to Smurf2 in mammalian cells suggests that,
similar to Smads 2 and 3, it may also recruit targets for destruction
by Smurf2 E3 ligase. RNF11 is a small RING-finger protein, similar
to ROC1 and APC11, which are components of the SCF and the
anaphase promoting complexes respectively (Chen et al, 2000;
Jackson et al, 2000; Maeda et al, 2001). These two ubiquitin ligase
complexes regulate Ub-mediated protein degradation during G1/S
and anaphase. The importance of the small ring-finger proteins
ROC1 and APC11 in these complexes suggests that RNF11 may
also have a role in multi-subunit E3 complexes.
In general, ubiquitin moieties are transferred from an E2 to a
catalysing ubiquitin protein ligase E3 and then on to the substrate
protein. However, the E2 enzyme for the HECT-type ligase Smurf2
is unknown. Our results suggest that interaction of RNF11 with
Smurf2 allows ubiquitination of Smurf2, and this is dependent
upon the presence of UbcH5a (Figure 5). This suggests that RNF11
is required for the ubiquitination of Smurf2 that is essential to its
ligase activity (Yagi et al, 1999). Interaction between UbcH5a and
RNF11 was confirmed in a similar but separate experiment
showing that UbcH5s, but not Ubc3, interacts with RNF11 in the
absence of Smurf2 (Figure 4). RNF11 is therefore a PY motif
containing RING-finger protein that may mediate activation of the
HECT-type E3 ligase Smurf2 by the E2 conjugating UbcH5
enzymes (Figure 5).
Smurf2 also interacts with the PY motif of Smad7, forming a
complex essential to the ubiquitination and degradation of TbRI. It
has been reported that the Smad7 protein suppresses TGFb
dependent induction of the 3TP-Lux reporter (Hayashi et al, 1997).
Transactivation and association of Smurf2 with Smad7 further
reduces this transcription activity due to degradation of the TGFb
RI (Hayashi et al, 1997; Kavsak et al, 2000). We hypothesised that
the PY motif of RNF11 could affect interactions with Smad7. This
was tested by us in a transcription–transactivation assay similar to
that used to illustrate Smad7/Smurf2 effects on TGFb responsive
gene transcription (Hayashi et al, 1997; Kavsak et al, 2000). As
expected, TGFb treatment induced 3TP-Lux reporter activity in
transfected cells, and this transcriptional activity was inhibited by
Smurf2 but not by RNF11 (Figure 6). However, the transcriptional
activity of the reporter gene was restored when increasing amounts
of RNF11 were used in conjunction with Smurf2 (Figure 6). This
suggests that RNF11 may interfere with the binding of Smad7 to
Smurf2, thus inhibiting the degradation of TbRI protein resulting
in restoration of transcription of reporter gene activity. Moreover,
the PY mutant of RNF11 which does not bind to Smurf2 is unable
to restore the activation of the 3TP reporter. Thus, our data
strongly support a role for RNF11 affecting the Smurf2/Smad7
protein–protein interactions involved in TGFb signalling. High-
level expression of Smurf2 has been found in oesophageal
squamous cell carcinoma (SCC) and seems to correlate with poor
prognosis in these patients (Fukuchi et al, 2002). The expression
pattern of RNF11 in human primary tumours is interesting when
compared to Smurf2 in that head and neck tumours including
oesophageal SCC samples expressed RNF11 in 63% of the surveyed
cases. This is particularly relevant in the light of the observed
overexpression of RNF11 in invasive breast cancers and its affects
on TGFb responsive gene activation (Figures 1 and 6).
Although Smad proteins inhibit cell proliferation, they can also
induce tumour invasion and metastasis. Similarly, in animal
models it has been reported that TGFb can inhibit early stages of
tumour development but stimulate later tumour progression and
metastasis. The interaction of RNF11 and Smurf2 could be
important here because it restores TGFb signalling and RNF11
could have multiple functions similar to Smad proteins. Perhaps,
RNF11 blocks some of the inhibitory effects of Smad7 on TGFb
signalling on cell proliferation and apoptosis, but leaves intact the
positive effects of this pathway on malignant progression.
An abundance of regulatory proteins, including growth factors
and their receptors, adaptor proteins involved in signal transduc-
tion, transcription factors and cell cycle regulating proteins, is
coordinated by balancing their synthesis and degradation. As
shown here, RNF11 interacts with ubiquitin E2 conjugating
enzymes and E3 ligases and thus could potentially facilitate the
degradation of specific substrate(s) involved in oncogenesis. The
ongoing identification of target proteins that are ubiquitinated in
the presence of RNF11 will allow us to determine the significance
of its role in tumorigenesis (Li and Seth, 2003). In addition, we are
investigating how its gene product can be used as a target for
molecular diagnosis and therapeutic intervention of breast and
other cancers.
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